HK1163689A1 - Methods and compositions for modulating ire1, src, and abl activity ire1src abl - Google Patents
Methods and compositions for modulating ire1, src, and abl activity ire1src ablInfo
- Publication number
- HK1163689A1 HK1163689A1 HK12104444.0A HK12104444A HK1163689A1 HK 1163689 A1 HK1163689 A1 HK 1163689A1 HK 12104444 A HK12104444 A HK 12104444A HK 1163689 A1 HK1163689 A1 HK 1163689A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- abl
- ire1src
- src
- compositions
- methods
- Prior art date
Links
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9717308P | 2008-09-15 | 2008-09-15 | |
| PCT/US2009/056993 WO2010031056A2 (en) | 2008-09-15 | 2009-09-15 | Methods and compositions for modulating ire1, src, and abl activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1163689A1 true HK1163689A1 (en) | 2012-09-14 |
Family
ID=42005819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12104444.0A HK1163689A1 (en) | 2008-09-15 | 2012-05-08 | Methods and compositions for modulating ire1, src, and abl activity ire1src abl |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8815885B2 (de) |
| EP (1) | EP2340248B1 (de) |
| JP (3) | JP6144873B2 (de) |
| CN (2) | CN104230901A (de) |
| AU (2) | AU2009290617B2 (de) |
| CA (1) | CA2737388C (de) |
| HK (1) | HK1163689A1 (de) |
| WO (1) | WO2010031056A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010031056A2 (en) | 2008-09-15 | 2010-03-18 | The Regents Of The University Of California | Methods and compositions for modulating ire1, src, and abl activity |
| CN102724975B (zh) * | 2009-11-03 | 2015-12-02 | 满康德股份有限公司 | IRE-1α抑制剂 |
| WO2012109238A2 (en) * | 2011-02-07 | 2012-08-16 | President And Fellows Of Harvard College | Methods for increasing immune responses using agents that directly bind to and activate ire-1 |
| US9186393B2 (en) * | 2011-09-02 | 2015-11-17 | The Children's Medical Center Corporation | Methods and compositions for reducing blood glucose |
| US9221798B2 (en) * | 2011-09-05 | 2015-12-29 | Zhejian Hisun Pharmaceutical Co., Ltd. | 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof |
| WO2013134774A1 (en) | 2012-03-09 | 2013-09-12 | Cornell University | Modulation of breast cancer growth by modulation of xbp1 activity |
| WO2014190207A1 (en) * | 2013-05-22 | 2014-11-27 | The Regents Of The University Of California | Aurora kinase inhibitors |
| DK3049521T3 (en) | 2013-09-25 | 2019-04-23 | Univ Cornell | Compounds for inducing antitumor immunity and methods thereof |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| WO2016022839A1 (en) * | 2014-08-06 | 2016-02-11 | The Regents Of The University Of California | Modulators of ire1 |
| CN106162913B (zh) * | 2015-04-21 | 2020-09-22 | 索尼公司 | 频谱协调装置和方法、无线通信系统中的装置和方法 |
| WO2018138358A1 (en) * | 2017-01-30 | 2018-08-02 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| TW201838981A (zh) | 2017-03-17 | 2018-11-01 | 美商建南德克公司 | 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法 |
| TWI831829B (zh) * | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| US20220048888A1 (en) | 2018-09-12 | 2022-02-17 | Genentech, Inc. | Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use |
| JP2022517189A (ja) | 2019-01-03 | 2022-03-07 | ジェネンテック， インコーポレイテッド | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 |
| AR118119A1 (es) | 2019-02-18 | 2021-09-22 | Genentech Inc | Compuestos de pirido-pirimidinilo y métodos de uso |
| US20220227730A1 (en) * | 2019-05-15 | 2022-07-21 | Cornell University | Treatment of fibrosis with ire1 small molecule inhibitors |
| KR102215967B1 (ko) * | 2019-05-28 | 2021-02-16 | 연세대학교 산학협력단 | IRE1α 키나아제 활성화제를 유효성분으로 포함하는 단백질 형태 이상 질환의 예방 또는 치료용 조성물 |
| WO2020252165A1 (en) | 2019-06-11 | 2020-12-17 | Genentech, Inc. | Quinazolinyl compounds and methods of use |
| US20220340546A1 (en) * | 2019-06-14 | 2022-10-27 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| KR20230118854A (ko) | 2020-11-13 | 2023-08-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | IRE1α 억제제 및 이의 용도 |
| KR20230118855A (ko) * | 2020-11-13 | 2023-08-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | IRE1α 억제제 및 이의 용도 |
| CN112616776B (zh) * | 2021-01-04 | 2022-04-29 | 王涛 | 脊髓亚急性联合变性病模型的制备方法 |
| CN114907350B (zh) * | 2021-02-10 | 2023-12-29 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物、制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
| DE60120193T2 (de) * | 2000-09-15 | 2007-03-29 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinasehemmer |
| ATE528303T1 (de) * | 2000-12-21 | 2011-10-15 | Vertex Pharma | Pyrazoleverbindungen als proteinkinasehemmer |
| WO2003026665A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| AU2005322855B2 (en) * | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| EP1746096A1 (de) * | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazol-Analoge zur Verwendung als Antikrebsmittel |
| EP2043651A2 (de) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Verfahren zur verwendung von igf1r und abl-kinase-modulatoren |
| WO2010031056A2 (en) | 2008-09-15 | 2010-03-18 | The Regents Of The University Of California | Methods and compositions for modulating ire1, src, and abl activity |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| IN2014DN04646A (de) | 2011-11-10 | 2015-04-03 | Aplix Sa |
-
2009
- 2009-09-15 WO PCT/US2009/056993 patent/WO2010031056A2/en active Application Filing
- 2009-09-15 CN CN201410379459.7A patent/CN104230901A/zh active Pending
- 2009-09-15 CA CA2737388A patent/CA2737388C/en active Active
- 2009-09-15 US US13/119,162 patent/US8815885B2/en active Active
- 2009-09-15 EP EP09813799.5A patent/EP2340248B1/de active Active
- 2009-09-15 AU AU2009290617A patent/AU2009290617B2/en not_active Ceased
- 2009-09-15 JP JP2011527045A patent/JP6144873B2/ja active Active
- 2009-09-15 CN CN200980145225.3A patent/CN102264728B/zh active Active
-
2012
- 2012-05-08 HK HK12104444.0A patent/HK1163689A1/xx not_active IP Right Cessation
-
2014
- 2014-07-02 US US14/322,765 patent/US9382230B2/en active Active
- 2014-08-14 JP JP2014165200A patent/JP2015017099A/ja not_active Withdrawn
-
2015
- 2015-08-10 AU AU2015210470A patent/AU2015210470A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041213A patent/JP6412968B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9382230B2 (en) | 2016-07-05 |
| CA2737388C (en) | 2017-07-11 |
| CN104230901A (zh) | 2014-12-24 |
| US20110319436A1 (en) | 2011-12-29 |
| US20150011575A1 (en) | 2015-01-08 |
| CN102264728A (zh) | 2011-11-30 |
| JP2012502916A (ja) | 2012-02-02 |
| WO2010031056A2 (en) | 2010-03-18 |
| EP2340248A4 (de) | 2012-06-20 |
| JP6144873B2 (ja) | 2017-06-07 |
| EP2340248B1 (de) | 2017-05-31 |
| WO2010031056A3 (en) | 2010-08-05 |
| US8815885B2 (en) | 2014-08-26 |
| JP6412968B2 (ja) | 2018-10-24 |
| CA2737388A1 (en) | 2010-03-18 |
| AU2009290617B2 (en) | 2015-05-14 |
| EP2340248A2 (de) | 2011-07-06 |
| CN102264728B (zh) | 2015-02-04 |
| JP2015017099A (ja) | 2015-01-29 |
| JP2017160197A (ja) | 2017-09-14 |
| AU2009290617A1 (en) | 2010-03-18 |
| AU2015210470A1 (en) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1163689A1 (en) | Methods and compositions for modulating ire1, src, and abl activity ire1src abl | |
| IL248652A0 (en) | Methods, compositions and devices for facilitating re-creation | |
| IL239959A0 (en) | Compounds and methods for modulating kinases and their use | |
| EP2068875A4 (de) | Zusammensetzungen und verfahren zur modulierung der sirtuin-aktivität | |
| EP2203058A4 (de) | Verfahren und verbindungen zur modulation der cannabinoidaktivität | |
| EP2203067A4 (de) | Zusammensetzungen und verfahren unter verwendung kohlenstoffhaltiger substanzen | |
| IL219418A0 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EP2501236A4 (de) | Verbindungen und verfahren zur kinase-modulation und anzeigen dafür | |
| EP2516438A4 (de) | Verbindungen und verfahren zur kinase-modulation und anzeigen dafür | |
| EP2304520A4 (de) | Systeme und verfahren für kollaborative interaktion | |
| EP2432774A4 (de) | Verbundstoffe, zusammensetzungen und verfahren zur modulierung des harnsäurespiegels | |
| EP2299828A4 (de) | Landwirtschaftliche zusammensetzungen mit niedriger aufwandmenge und verfahren zu ihrer verwendung | |
| EP2197434A4 (de) | Resveratrol enthaltende zusammensetzungen zur modulierung der genprodukt-konzentration oder aktivität | |
| PL2129680T3 (pl) | Łączone kompozycje cząsteczek antysensownych o strukturze spinki do włosów oraz sposoby modulacji ekspresji | |
| EP2235201A4 (de) | Verfahren und zusammensetzungen zum testen von homozystein | |
| IL216388A0 (en) | New compounds, pharmaceutical composition and methods relating thereto | |
| HK1161543A1 (zh) | 促進紅細胞生成的化合物和方法 | |
| EP2164978A4 (de) | Zusammensetzungen und verfahren zur modulation von adamts13-aktivität | |
| EP2114981A4 (de) | Verbindungen und verfahren zur modulation der proteinexpression | |
| LT2320739T (lt) | Farmacinės kompozicijos ir jų stabilizavimo būdai | |
| EP2313516A4 (de) | Zusammensetzungen und verfahren zur modulierung der nod-like-rezeptoraktivität und ihre verwendung | |
| EP2015782A4 (de) | Zusammensetzungen und verfahren zur modulation von genexpression | |
| EP2205271A4 (de) | Zusammensetzungen und verfahren für therapien auf ribonukleasebasis | |
| HK1141682A1 (en) | New compositions and methods for cell killing | |
| HRP20150021T1 (en) | Phenanthrenone compounds, compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230915 |